Method for the Reduction of Dangerous Blood Sugar Levels

ABSTRACT

The present invention relates to a method and procedure for reducing immediate serum glucose levels without resort to drugs. Specifically, the invention discloses a regular regimen comprising modest exercise, daily nutritional supplements and a series of specific, time sensitive steps, which, when followed will optimize the effects of the invention.

REFERENCE TO PROVISIONAL PATENT FILLING

On February 10, 2007, the Inventor filed a provisional patent disclosureentitled Method for the Long-Term Reduction of Dangerous Blood SugarLevels from which this application is derived.

Circumstances of Conception.

The Inventor suffers from iron overloading. This is a common result ofthe contemporary American diet which includes too much fructose andvitamin c (both of which cause too much iron to be absorbed). The extrairon builds up in organs and damages them. Without treatment, thedisease can cause these organs to fail.

Healthy people usually absorb about 10 percent of the iron contained inthe food they eat to meet the body needs. People with a geneticinclination to absorb excess iron suffer from hemochromatosis andfrequently become diabetic. Their body has no natural way to rid itselfof the excess iron, so it is stored in body tissues, especially theliver, heart, and pancreas.

Excess iron depletes the body's ability to process chromium^(i).Chromium is a necessary co-factor with insulin, in the normal digestionof glucose and other sugars^(ii). Without chromium to assist theinsulin, the metabolism is only one-sixth as effective in processingglucose^(iii) and the sufferer is deemed to have Type II DiabetesMellitus, the complications of which (heart disease, hypertension, livercancer, kidney failure, strokes, etc.) are the largest causes of earlydeath worldwide.

Upon being diagnosed as Diabetic, the Inventor had to make a choice toeither quietly accept his fate along with millions of other Diabetics orfight it. He chose to learn all he could of the disease and search for acure. Common medical wisdom says that Diabetes is incurable andsufferers can only hope to mitigate the symptoms and must accept asignificantly degraded quality of life. The Inventor found otherwise.

Mechanism of Sugar Metabolism

Soon after the introduction of sugars into the blood stream, thepancreas begins production of insulin. The insulin, when injected intothe blood stream, unites with a co-factor, a chromium-bindingoligopeptide produced in the liver, called Glucose Tolerance Factor^(iv)(GTF), or, sometimes, Low Molecular Weight Chromium factor (LMWCr). Thisoligopeptide normally contains an ion of Chromium in the plus 3oxidation state (Cr+3) and is part of an auto-amplification mechanismfor insulin signaling.

The insulin with its GTF co-factor has been shown to activate thetyrosine kinase activity of the insulin receptor of cells in response toinsulin. This allows the Cr3+ to move from the blood into the cells ofthe insulin-sensitive tissues, which amplifies the importation ofglucose into the cells. The oligopeptide then becomes inactive and asChromodulin, is filtered by the kidneys for elimination in the urine. Ifthere is insufficient Chromium in the Liver, the oligopeptide still isproduced but is one sixth as effective in catalyzing the insulin processas it is with the Cr+3 ion present.

Chromium normally enters the body as a trace element in food. FreeChromium, however, cannot exist in the blood stream due to the chelatingeffect of the sugars present therein. Free Chromium is immediately, andalmost entirely complexed out by blood glucose as the chelate ChromiumGluconate, which is eliminated in the urine.

To survive transit from the intestines to the liver, where the GTF isproduced, Cr+3 in the intestines is loaded onto a molecule known asTransferrin, a plasma protein which transports both Iron and Chromium tothe liver. In healthy persons, the Transferrin ratio of Chromium to Ironis 7:3^(v), however, if there is insufficient Chromium in the diet, orif there is excess Iron in the system, this ratio changes dramatically.In Hemochromatosis victims, the Transferrin molecules are almostentirely loaded with Iron.

Chromium, offloaded from the Transferrin, is stored in the Liver,kidneys, bone marrow and other soft tissues^(vi). The most significantsource of chromium, therefore for humans has previously been organ meatssuch as liver and kidneys. These food sources are no longer consumed insignificant amounts, and thus the chromium contained therein is notavailable. In modern diets, this optimal 7:3 mix is usually out ofbalance because of two factors. First, the highly refined foods in themodern diet remove most of the naturally present chromium in theprocessing. Second, the over-abundance of dietary carbohydrates loadsthe gut with glucose, which readily forms Chromium Gluconate, thuseliminating most of the free chromium which is present in the gut priorto its reaching the transferrin.

With each cycle of the iron and chromium loaded transferrin between theintestinal walls and the liver, the ratio of iron to chromium containedin the transferrin tends to change. If the metal ion transport ratio ofthe transferrin reaches 60% iron and 40% chromium, the liver must dealwith twice the optimal iron load and slightly more than half of therequired amount of chromium.

This prevailing tendency, of accumulating excess iron at the expense ofchromium, is implicated as one of the potential causes for not onlydiabetes mellitus, but also heart disease, high lipids, hyper tension,cirrhosis of the liver, gout, macular degeneration and glaucoma.

The highest levels of chromium are present at the time of birth. Severallarge population studies indicate that chromium in the tissues ofcarbohydrate overloaded humans declines continuously throughout thecourse of lifer. The normal daily demand for production of GTF willeventually deplete the liver's store of Cr+3 if not replenished throughthe diet. Once the liver is unable to provide a Cr+3 ion for every GTFproduced, the normal sugar metabolism becomes inefficient and DiabetesMilletis ensues.

The Insulin Resistance Paradigm:

Insulin resistance is the phrase given to the phenomenon of a person'smaintaining higher than normal blood sugar levels even though thepancreas is producing a normal amount of insulin. Insulin resistance isalmost always associated with an excess of fat stored in the liver,which is called “Fatty Liver” syndrome.

Glucose is a necessary component in normal metabolism, but in diabetics,this metabolism gets out of balance. When cells are in need of glucose,there is an enzymatic signal sent to the pancreatic alpha cells whichrespond by releasing glucagon, which in turn triggers the release, bythe liver, of more glucose into the blood. However, the presence of thisblood glucose stimulates the pancreatic beta cells to create insulin andinject it into the blood stream. But when the GTF is missing thenecessary chromium ion, the insulin is only one-sixth as effective intransporting the available glucose into the cells. The glucose-starvedcells continue to emit the enzymatic signal to produce more glucose,completing the cyclic dysfunction. Thus, the pancreas is simultaneouslyproducing both Glucagon, to trigger glucose delivery to the cells andInsulin, to metabolize the extra glucose.

Consuming excess carbohydrates at meals does nothing to correct theshortage of glucose transport into the cells. The metabolic process hasbeen impaired by an endemic shortage of chromium, and dramaticallyreduced insulin effectiveness. This suggests that the (fatty) liver canmaintain high blood glucose levels for an extended period of time.

Diabetics achieve only limited satiation from food they ingest becausethe abundance of glucose in their systems is not drawn into the cellsthat need the glucose. The diabetic normally has an adequate supply offat which the liver can readily convert to glucose. Obesity frequentlyresults, as the unsatisfying meals leave the victim continuously hungryand therefore still eating. In addition, un-metabolized glucose isultimately converted by the liver to further fat for storage. Fatigue isalso a common result of the intracellular glucose shortage as the musclecells are denied adequate amounts of energy (glucose).

In summary, newly diabetic persons usually have sufficient insulin toadequately handle the daily glucose needs of the cells, however, thechromium-depleted GTF is unable to facilitate the efficient transport ofglucose across the cell walls. This has the effect of building the serumglucose to dangerous levels and has the dual, undesirable result ofoverworking and thus wearing out the pancreas while at the same timesubjecting tissues to toxic levels of glucose. After prolonged absenceof Cr+3, the pancreas beta cells become over-worked and eventually areunable to produce sufficient Insulin.

The most common form of adult onset diabetes, therefore, is the resultof the body's supplies of available chromium being depleted, which leadsto a deficiency of chromium at the liver during the synthesis of GTF.Generally, women have higher chromium levels than men^(ix), however,during pregnancy, woman must provide the high levels of chromiumdemanded by the developing fetus, which depletes her natural stores.Pregnant women thus often develop Gestational Diabetes, brought on bythe forced chromium shortage. This condition is usually reversible afterbirth providing the woman can replenish the chromium stores in herbody's storage locations. Patients on prolonged intravenous feeding candevelop Diabetes simply due to the absence of Cr+3 in the drip. Thiscondition is almost instantly reversible by the simple addition of aslittle as 250 micrograms of Cr+3 per day over a 2 week period.

Purposes and Advantages of Invention.

An object of this invention is to disclose a long-term program effectivein reversing the Chromium deficiency in Type II Diabetes victims, aFurther objective is to reduce or even remove the need for daily insulininjections. Further objectives are to provide a method which allowdiabetics to:

-   -   (1) retire for the evening with relatively low glucose numbers,    -   (2) restore more normal sleep patterns,    -   (3) reduce depression and carbohydrate craving,    -   (4) increase energy levels, muscle mass, workloads, weight loss,        and overall sense of well being.

This invention provides diabetics with the ability to temporarilyexpedite a dramatic increase in the amount of serum glucose importedinto the muscle cells. Because these cells are temporarily satiated withglucose, the glucagon signaling apparatus is interrupted, the liversuspends the release of glucose into the blood, and lower overnightglucose levels become much more obtainable.

Although the exercise regimen disclosed herein is intended as a part ofa long-term program for restoring the body's depleted Chromium stores,it is also effective as a one-time treatment to mitigate the effects ofa carbohydrate overdose. A Type III Diabetic who has ingested adangerous amount of carbohydrates may rapidly and dramatically reducehis/her blood serum glucose levels by simply using the exercise regimendisclosed herein as soon after exposure to the excess carbohydrates aspossible.

PREFERRED EMBODIMENT

The invention consists of components which give Type II Diabetics theability to effect dramatic, short-term reduction of blood sugar levelsand to eventually replenish the body's stores of Chromium (III). Thecomponents are as follows:

a. A daily regimen of vitamins and tablets comprising

-   -   i. Twice daily doses of a compound comprising the Chromium        complex of an Organic Acid such as Picolinate, Nicotinate,        Glycinate or other having a chromium content of between 100 and        500 micrograms of Chromium.    -   ii. 200-1,000 milligram daily dose of a vaso-dilator/blood        thinner comprising aspirin, niacin and L-Arginine.    -   iii. doses of liquid Ionic chromium in the concentration of        between 100-500 parts per million, such that each dose contains        between 100 and 1,500 micrograms of chromium. Such compound is        administered in a fashion which will introduce massive amounts        of Cr(III) into the blood stream in a rapid manner, such as        sublingually.

b. A complimentary exercise regimen comprising at least one dailyaerobic exercise session of at least one-half hour each. The exerciseshould elevate and hold the heart rate at or above 60% of the maximum asestablished by the American Medical Association for the duration of theworkout.

c. A method of administering the daily regimen:

-   -   i. The Chromium Organic acid compound is ingested at least twice        per day, usually in the morning and in the evening.    -   ii. Approximately 10 minutes prior to each work out, The person        ingests the vaso-dilator/blood thinner.    -   iii. Immediately prior to workout, the person places the Ionic        Chromium complex under the tongue (sublingual) and holds it        there during the exercise for as long as possible before        swallowing.    -   iv. Approximately mid-way through the work out, the person        repeats the sublingual administration of the Ionic Chromium        complex.        Closest known Prior Art.

Patent No. Inventor Date Title 4,571,391 Riley, et al Feb. 18, Chromiumacetylacetonate as a dietary 1986 supplement and pharmaceutical agent4,923,855 Jensen May 8, 1990 Synthetic GTF chromium material and processtherefor 4,954,492 Jensen Sep. 4, Synthetic GTF chromium material for1990 decreasing blood lipid levels and process therefor 5,087,623Boynton, et al Feb. 11, Chromic picolinate treatment 1992 5,087,624Boynton, et al Feb. 11, Chromic picolinate treatment 1992 5,194,615Jensen Mar. 16, 1993 Synthetic GTF chromium nicotinate material and itspreparation 5,567,736 Buchman, et Oct. 22, Use of a choline salt toinhibit fatty liver al 1996 in patients receiving total parenteralnutrition 5,905,075 Harpe, et al May 18, 1999 Chromium nicotinatecompositions and uses thereof 5,948,772 de la Harpe, et Sep. 7, Chromiumpicolinate compositions and al 1999 uses thereof 5,962,030 Fine Oct. 5,1999 Dietary supplement and method of treatment for diabetic control5,980,905 de la Harpe, et Nov. 9, Chromium polynicotinate compositionsal 1999 and uses thereof 6,093,711 de la Harpe, et Jul. 25, 2000Enteric-coated chromium picolinate al compositions and uses thereof6,100,250 de la Harpe, et Aug. 8, 2000 Enteric-coated chromiumpolynicotinate al compositions and uses thereof 6,100,251 de la Harpe,et Aug. 8, 2000 Chromium polynicotinate compositions al 6,136,317 de laHarpe, et Oct. 24, Chromium picolinate compositions al 2000 6,143,301 dela Harpe, et Nov. 7, Chromium picolinate compositions and al 2000 usesthereof 6,147,070 Facchini Nov. 14, Methods and compositions for 2000controlling iron stores to treat and cure disease states 6,203,819 FineMar. 20, 2001 Dietary supplement and method of treatment for diabeticcontrol 6,251,888 de la Harpe, et Jun. 26, 2001 Chromium picolinatecompositions and al uses thereof 6,251,889 de la Harpe, et Jun. 26, 2001Chromium picolinate compositions al 6,258,848 Fantus Jul. 10, 2001Methods and compositions for increasing insulin sensitivity 6,323,192Harpe, et al Nov. 27, Chromium polynicotinate compositions 2001 and usesthereof for absorption of essential metals 6,432,942 de la Harpe, etAug. 13, 2002 Chromium picolinate compositions and al uses thereof6,440,931 Remmereit, et Aug. 27, 2002 Conjugated linoleic acid intreatment al and prophylaxis of diabetes 6,471,998 de la Harpe, et Oct.29, Chromium picolinate compositions al 2002 6,541,005 Yegorova Apr. 1,2003 Compositions and methods for reducing or controlling bloodcholesterol, lipoproteins, triglycerides and atherosclerosis 6,544,525Yegorova Apr. 8, 2003 Compositions and methods for reducing orcontrolling blood cholesterol, lipoproteins, triglycerides andatherosclerosis 6,548,687 Yu, et al Apr. 15, 2003 Chromium L-threonate,process for preparation of the same and their use 6,576,242 YegorovaJun. 10, 2003 Compositions and methods for reducing or controlling bloodcholesterol, lipoproteins, triglycerides and atherosclerosis 6,660,293Giordano, et al Dec. 9, Compositions and methods for 2003 prophylacticand therapeutic supplementation of nutrition in subjects 6,689,383Anderson, et Feb. 10, Chromium-histidine complexes as al 2004 nutrientsupplements 6,713,469 de la Harpe, et Mar. 30, 2004 Chromium picolinatecompositions and al uses thereof 6,809,115 Katz, et al Oct. 26, Methodsand compositions for the 2004 treatment of diabetes, the reduction ofbody fat, improvement of insulin sensitivity, reduction ofhyperglycemia, and reduction of hypercholesterolemia with chromiumcomplexes, conjugated fatty acids, and/or conjugated fatty alcohols6,814,983 Giordano, et al Nov. 9, Compositions and methods for nutrition2004 supplementation 6,818,229 Cefali, et al Nov. 16, Intermediaterelease nicotinic acid 2004 compositions for treating hyperlipidemia6,818,233 Perkes Nov. 16, Dietary supplements containing natural 2004ingredients 6,852,690 Nauck, et al Feb. 8, 2005 Method and compositionfor enhanced parenteral nutrition 6,852,760 Fine, et al Feb. 8, 2005Compositions and methods for treatment for glucose metabolism disorders6,863,904 Giordano, et al Mar. 8, 2005 Compositions and methods forprophylactic and therapeutic supplementation of nutrition in subjects6,893,627 Ribnicky, et al May 17, 2005 Method for treating type 2diabetes with an extract of Artemisia 6,893,656 Blitzer, et al May 17,2005 Athletic patch 6,955,883 Margus, et al Oct. 18, Life sciencesbusiness systems and 2005 methods 6,967,030 Wright, et al Nov. 22,Formulation for insulin and glucose 2005 control 6,967,204 Fryburg, etal Nov. 22, Treatment of insulin resistance 2005 syndrome and type 2diabetes with PDE9 inhibitors 6,995,166 Giordano, et al Feb. 7, 2006Method and composition for supplementation of nutritional deficienciesin renal patients ^(i)Sargent T, Lim TH, Jenson, RL: “Reduced ChromiumRetention in Patients with Hemochromatosis, a Possible Basis ofHemochromatotic Diabetes” Metabolism: 1979: 28:1, p 70-79 ^(ii)Maher,Timothy J. Chromium and Other Minerals in Diabetes Mellitus, U.S.Pharmacist, 2000: 24:11 ^(iii)Vincent, J., “Biochemistry of Chromium, J.Nutrition 2000; 130: 715-718 ^(iv)Vincent, ibid ^(v)Brock, J. H.,“Transferrins.” Harrison P. (ed) Metalloproteins 1985: vol.2: 183-262MacMillan, London ^(vi)Lim, T, Sargent, T., Kusubov, N. “Kinetics ofTrace Element Chromium (III) in the Human Body” Am J. Physiology, 1983:244(4): R445-54 ^(vii)Davies, S., et al, “Age-related decreases inchromium levels in 51,665 hair, sweat, and serum samples from 20,872patients - implications for the prevention of cardiovascular disease andType II diabetes mellitus”, Metabolism, 1997; 46(5) 469-73 ^(viii)Jiang,G., Zhang, B. “Glucagon and Regulation of Glucose Metabolism” Am JPhsiol Endocrinol Metab. 2003 284: E671-8 ^(ix)Davies, ibid^(x)Jeejeehboy, K., et al, “Chromium Deficiency, Glucose Intolerance andNeuropathy reversed by Chromium Supplementation in a Patient ReceivingLong-Term Parenteral Nutrition:” Am J. Clin Nutr. 1977; 30*pp. 531-8

1. A long-term serum glucose reduction method consisting of a pluralityof daily doses of a Chromium (III) compound having a chromium content ofbetween 100 and 500 micrograms of Chromium; a plurality of frequentexercise sessions wherein a vaso-dilator/blood thinner is ingestedshortly before beginning exercise; upon beginning exercise, an Ionicsolution containing between 100 and 1,500 micrograms of Chromium (III)is administered; The person exercises sufficiently to raise his/herpulse rate to between 60% and 85% of the maximum as established by theAmerican Medical Association and maintains that pulse rate for at least15 minutes.
 2. The method of claim 1 wherein said exercise sessions areat least daily.
 3. The method of claim 1, wherein said Chromium (III)compound comprises any Halide, any Amino Acid, Picolinate, Nicotinate,Ascorbate, or Oxalate.
 4. The method of claim 1 wherein saidvaso-dilator/blood thinner comprises aspirin, niacin or L-Arginine. 5.The method of claim 1 wherein said Ionic solution comprises thedissolved Chromium salt of any halide or any organic acid.
 6. The methodof claim 1 wherein said Ionic Chromium solution is applied sublingually.7. The method of claim 1 wherein said Ionic Chromium solution is appliednasally.
 8. The method of claim 1 wherein said Ionic Chromium solutionis applied through a skin patch.
 9. A short-term serum glucose reductionmethod consisting of an exercise session wherein a vaso-dilator/bloodthinner is ingested shortly before beginning exercise; upon beginningexercise, an Ionic Chromium solution containing Chromium (III) levels ofbetween 100 and 1,500 micrograms of Chromium is administered; The personexercises sufficiently to raise his/her pulse rate to between 60% and85% of the maximum as established by the American Medical Associationand maintains that pulse rate for at least 15 minutes.
 10. The method ofclaim 9 wherein said vaso-dilator/blood thinner comprises aspirin,niacin or L-Arginine.
 11. The method of claim 9 wherein said Ionicsolution comprises the dissolved Chromium salt of any halide or anyorganic acid.
 12. The method of claim 9 wherein said Ionic Chromiumsolution is applied sublingually.
 13. The method of claim 9 wherein saidIonic Chromium solution is applied nasally.
 14. The method of claim 9wherein said Ionic Chromium solution is applied through a skin patch.